AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31648336 — intervention group
Group type: EXPERIMENTAL
Intervention: Flt3L measurement
Number of subjects: 140
Study 28982943 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training for 3 months
Number of subjects: 64
Study 28982943 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 64
Study 26026461 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiblock copolymers with high block-size polydispersity and lamellar structures
Number of subjects: 0
Study 26026461 — intervention group
Group type: EXPERIMENTAL
Intervention: Block-size distribution P(k) for random copolymers
Number of subjects: 0
Study 23387416 — intervention group
Group type: EXPERIMENTAL
Intervention: IMAAC (600 mg)
Number of subjects: 60
Study 23387416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (600 mg)
Number of subjects: 60
Study 23387416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20447833 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen only
Number of subjects: 131
Study 20447833 — intervention group
Group type: COMPARATOR
Intervention: Wedge mastectomy only
Number of subjects: 131
Study 18649152 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Programming System (RPS)
Number of subjects: 24
Study 18649152 — intervention group
Group type: COMPARATOR
Intervention: Standard on-site CI programming
Number of subjects: 24
Study 17679046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro/Col
Number of subjects: 49
Study 17679046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro/Cr
Number of subjects: 49
Study 17679046 — intervention group
Group type: EXPERIMENTAL
Intervention: Col/Cr
Number of subjects: 49
Study 17679046 — intervention group
Group type: COMPARATOR
Intervention: Pro
Number of subjects: 49
Study 15096445 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.5%
Number of subjects: 60
Study 15096445 — intervention group
Group type: COMPARATOR
Intervention: ropivacaine 0.5%
Number of subjects: 60
Study 11793035 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (oral tacrolimus 0.2 mg/kg daily + oral prednisone)
Number of subjects: 249
Study 11793035 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (oral tacrolimus 0.2 mg/kg daily + oral prednisone + oral azathioprine)
Number of subjects: 249
Study 9551778 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g dextrose tablets and 15 mg nicotine transdermal patch
Number of subjects: 308
Study 9551778 — intervention group
Group type: COMPARATOR
Intervention: dextrose and placebo patch
Number of subjects: 308
Study 9551778 — intervention group
Group type: COMPARATOR
Intervention: placebo tablets and nicotine patch
Number of subjects: 308
Study 9551778 — intervention group
Group type: COMPARATOR
Intervention: placebo tablets and placebo patch
Number of subjects: 308
Study 7998359 — intervention group
Group type: EXPERIMENTAL
Intervention: Padma-28 (340 mg dried herbal mixture, 2 tablets twice daily for four months)
Number of subjects: 36
Study 7998359 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 36
Study 3176957 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion epidural analgesia (EDA) with bupivacaine throughout delivery (group B)
Number of subjects: 180
Study 3176957 — intervention group
Group type: COMPARATOR
Intervention: No infusion analgesia in the second stage of labor (group A)
Number of subjects: 180
Study 31785179 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular dental attendance
Number of subjects: 3553
Study 31785179 — intervention group
Group type: COMPARATOR
Intervention: Inconsistent dental attendance
Number of subjects: 3553
Study 30380948 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogens (CEE) plus 100 mg micronized progesterone (MP)
Number of subjects: 123
Study 30380948 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg CEE plus 100 mg MP
Number of subjects: 123
Study 30380948 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg CEE plus 10 mg dydrogesterone
Number of subjects: 123
Study 27315664 — intervention group
Group type: COMPARATOR
Intervention: Single fraction of 8 Gy
Number of subjects: 1157
Study 27315664 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 fractions of 4 Gy
Number of subjects: 1157
Study 27315664 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 1157
Study 27315664 — intervention group
Group type: EXPERIMENTAL
Intervention: High pain score and intake of opioids
Number of subjects: 1157
Study 27315664 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor performance score
Number of subjects: 1157
Study 25691501 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia divinorum
Number of subjects: 30
Study 25691501 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 30
Study 23868890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received smoking cessation intervention)
Number of subjects: 168
Study 23868890 — intervention group
Group type: COMPARATOR
Intervention: Control group (received no specific smoking cessation intervention)
Number of subjects: 168
Study 23868890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 168
Study 23868890 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168
Study 21138388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular prolotherapy (dextrose water)
Number of subjects: 48
Study 21138388 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular steroid injection (triamcinolone acetonide)
Number of subjects: 48
Study 17888020 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week combined exercise group (EG, n = 8)
Number of subjects: 17
Study 17888020 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 9)
Number of subjects: 17
Study 16191133 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement plus behavioral treatment
Number of subjects: 383
Study 16191133 — intervention group
Group type: COMPARATOR
Intervention: Nicotine replacement alone
Number of subjects: 383
Study 12826989 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 14
Study 12826989 — intervention group
Group type: EXPERIMENTAL
Intervention: Meprobamate (2,400 mg)
Number of subjects: 14
Study 12826989 — intervention group
Group type: EXPERIMENTAL
Intervention: Butabarbital (400 mg)
Number of subjects: 14
Study 12826989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10586177 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg)
Number of subjects: 17
Study 10586177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 17
Study 10586177 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 17
Study 8966003 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 118
Study 8966003 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 118
Study 8966003 — intervention group
Group type: COMPARATOR
Intervention: Laser alone
Number of subjects: 118
Study 1670723 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission reinforcement therapy (teniposide, cytarabine, high‐dose methotrexate)
Number of subjects: 358
Study 1670723 — intervention group
Group type: EXPERIMENTAL
Intervention: Four pairs of drugs rotated weekly or every 6 weeks
Number of subjects: 358
Study 1670723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy
Number of subjects: 358
Study 1670723 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-risk patients received 1800 cGy cranial irradiation after 1 year of remission
Number of subjects: 358
Study 6343175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 49
Study 6343175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 30959514 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (50 mg/kg p.o.)
Number of subjects: 20
Study 30959514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28826246 — intervention group
Group type: EXPERIMENTAL
Intervention: Full programme (educational lecture + conversation)
Number of subjects: 38
Study 28826246 — intervention group
Group type: COMPARATOR
Intervention: Conversation only
Number of subjects: 38
Study 27128712 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg m(‐2)) and cyclophosphamide (600 mg m(‐2)) every 14 days for four cycles
Number of subjects: 17
Study 27128712 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg m(‐2)) and cyclophosphamide (600 mg m(‐2))
Number of subjects: 17
Study 27128712 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin exposure
Number of subjects: 17
Study 27128712 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and NT‐proBNP
Number of subjects: 17
Study 24888266 — intervention group
Group type: EXPERIMENTAL
Intervention: Open gastric mobilization and right thoracotomy
Number of subjects: 0
Study 24888266 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric mobilization and right thoracotomy
Number of subjects: 0
Study 24888266 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally minimally invasive surgery (Bristol center only)
Number of subjects: 0
Study 24888266 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes measures
Number of subjects: 0
Study 22748455 — intervention group
Group type: EXPERIMENTAL
Intervention: Circadian Rhythm (CR) group
Number of subjects: 90
Study 22748455 — intervention group
Group type: COMPARATOR
Intervention: Continuous Sedation (CS) group
Number of subjects: 90
Study 22748455 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand Sedation (DS) group
Number of subjects: 90
Study 22748455 — intervention group
Group type: COMPARATOR
Intervention: Daily Interruption (DI) group
Number of subjects: 90
Study 19694630 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine monotherapy for 12 weeks
Number of subjects: 17
Study 19694630 — intervention group
Group type: COMPARATOR
Intervention: Prior lithium monotherapy
Number of subjects: 17
Study 17627232 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet cell transplantation (ICT)
Number of subjects: 21
Study 17627232 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 21
Study 18022033 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg per day
Number of subjects: 4105
Study 18022033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4105
Study 14499049 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine data collection
Number of subjects: 0
Study 10745071 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg gossypol/day for 12 or 16 weeks, then randomized to either 7.5 or 10 mg/day for 40 weeks
Number of subjects: 151
Study 10745071 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/day gossypol
Number of subjects: 151
Study 10745071 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day gossypol
Number of subjects: 151
Study 10745071 — intervention group
Group type: EXPERIMENTAL
Intervention: gossypol treatment
Number of subjects: 151
Study 9363971 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 1 (30% fat)
Number of subjects: 444
Study 9363971 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 2 (26% fat)
Number of subjects: 444
Study 9363971 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 3 (22% fat)
Number of subjects: 444
Study 9363971 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 4 (18% fat)
Number of subjects: 444
Study 9363971 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 1 (30% fat) for CHL
Number of subjects: 444
Study 9363971 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 2 (26% fat) for CHL
Number of subjects: 444
Study 9363971 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 3 (25% fat) for CHL
Number of subjects: 444
Study 1529683 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion using the Solcotrans Orthopaedic device
Number of subjects: 56
Study 1529683 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood transfusion (Control)
Number of subjects: 56
Study 2936546 — intervention group
Group type: EXPERIMENTAL
Intervention: special astringent cream under disposable polyethylene gloves
Number of subjects: 64
Study 2936546 — intervention group
Group type: COMPARATOR
Intervention: cotton inner gloves under polyethylene gloves
Number of subjects: 64
Study 31246926 — intervention group
Group type: EXPERIMENTAL
Intervention: Night optical device (NOD) technology in blackout conditions (BC)
Number of subjects: 6
Study 31246926 — intervention group
Group type: COMPARATOR
Intervention: Normal light conditions (LC)
Number of subjects: 6
Study 29528455 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar sympathetic block with 0.25% bupivacaine
Number of subjects: 4
Study 29528455 — intervention group
Group type: COMPARATOR
Intervention: Sham needle placement
Number of subjects: 4
Study 25994357 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief tailored feedback report plus three motivational interviewing‐based calls from trained peer counselors (n=40)
Number of subjects: 60
Study 25994357 — intervention group
Group type: COMPARATOR
Intervention: Report only (n=20)
Number of subjects: 60
Study 24811605 — intervention group
Group type: EXPERIMENTAL
Intervention: CICS (BD Nexiva™)
Number of subjects: 359
Study 24811605 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter
Number of subjects: 359
Study 23402680 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX plus physical therapy (PT)
Number of subjects: 40
Study 23402680 — intervention group
Group type: COMPARATOR
Intervention: BTX only (control group)
Number of subjects: 40
Study 23402680 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX plus PT
Number of subjects: 40
Study 19809408 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort (SJW)
Number of subjects: 70
Study 19809408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 18630536 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture combined with body acupuncture
Number of subjects: 72
Study 18630536 — intervention group
Group type: COMPARATOR
Intervention: Medication group (oral administration of Betaloc and Oryzanol)
Number of subjects: 72
Study 15995098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case-management intervention
Number of subjects: 273
Study 15995098 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 273
Study 12374459 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine plus triiodothyronine (T4 + T3)
Number of subjects: 0
Study 12374459 — intervention group
Group type: COMPARATOR
Intervention: Thyroxine alone (T4)
Number of subjects: 0
Study 10352048 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a female relative as a labor companion
Number of subjects: 109
Study 10352048 — intervention group
Group type: COMPARATOR
Intervention: Labor without family members present (Control)
Number of subjects: 109
Study 7854155 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (Phe)
Number of subjects: 0
Study 7854155 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (Ang II)
Number of subjects: 0
Study 1748852 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliad training on simulated patient case presentations
Number of subjects: 0
Study 1748852 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 6417279 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 164
Study 6417279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 30624279 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined thresholds for patient's age, PaO2/FIO2, plateau pressure, and extrapulmonary organ failure
Number of subjects: 1200
Study 29273130 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch subcutaneous allergen immunotherapy (AIT) for 24 months
Number of subjects: 28
Study 29273130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 29273130 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch subcutaneous allergen immunotherapy (AIT)
Number of subjects: 28
Study 26562368 — intervention group
Group type: EXPERIMENTAL
Intervention: Early HepB (administered within a few hours after birth)
Number of subjects: 182
Study 26562368 — intervention group
Group type: COMPARATOR
Intervention: Late HepB (administered after the repeat CRP)
Number of subjects: 182
Study 24934774 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg diazepam nasal spray (NS)
Number of subjects: 24
Study 24934774 — intervention group
Group type: COMPARATOR
Intervention: 20mg diazepam rectal gel (RG)
Number of subjects: 24
Study 24934774 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intranasal and rectal treatments
Number of subjects: 24
Study 22092485 — intervention group
Group type: COMPARATOR
Intervention: DBBM (deproteinized bovine bone mineral) with collagen membrane
Number of subjects: 12
Study 22092485 — intervention group
Group type: EXPERIMENTAL
Intervention: NCHA (nanocrystalline hydroxyapatite) with collagen membrane
Number of subjects: 12
Study 22092485 — intervention group
Group type: EXPERIMENTAL
Intervention: NCHA
Number of subjects: 12
Study 22092485 — intervention group
Group type: COMPARATOR
Intervention: DBBM
Number of subjects: 12
Study 22092485 — intervention group
Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 12
Study 18342858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transvaginal needle ovarian drilling (UTND; n = 82)
Number of subjects: 163
Study 18342858 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic electrosurgery ovarian drilling (n = 81)
Number of subjects: 163
Study 17484865 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg
Number of subjects: 509
Study 17484865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study 16091056 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 497
Study 16091056 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 497
Study 16091056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study 12359605 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine 125 (125I) brachytherapy
Number of subjects: 996
Study 12359605 — intervention group
Group type: COMPARATOR
Intervention: Charged particle radiation (proton or helium ion)
Number of subjects: 996
Study 9802271 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-supervised treatment
Number of subjects: 216
Study 9802271 — intervention group
Group type: COMPARATOR
Intervention: Direct observation (DO) treatment
Number of subjects: 216
Study 9802271 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-supervised treatment (retreatment patients)
Number of subjects: 216
Study 9802271 — intervention group
Group type: COMPARATOR
Intervention: Direct observation (DO) treatment (retreatment patients)
Number of subjects: 216
Study 7805979 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspiration (MVA)
Number of subjects: 1423
Study 7805979 — intervention group
Group type: COMPARATOR
Intervention: Sharp Curettage
Number of subjects: 1423
Study 2678426 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 18
Study 2678426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1190414 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration of adrenaline in lignocaine for haemostasis
Number of subjects: 200
Study 1190414 — intervention group
Group type: COMPARATOR
Intervention: Enflurane anaesthesia without adrenaline
Number of subjects: 200
Study 31419597 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistically‐based treatment of passive sentence production and comprehension (N = 14, treatment group)
Number of subjects: 19
Study 31419597 — intervention group
Group type: COMPARATOR
Intervention: Natural history group (N = 5, control group)
Number of subjects: 19
Study 31419597 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 19
Study 28067610 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive rehabilitation (CR) program (Memory Match, 3 weeks, nine sessions)
Number of subjects: 43
Study 28067610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CR program)
Number of subjects: 43
Study 24373522 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation-induced placebo (wound gel)
Number of subjects: 22
Study 24373522 — intervention group
Group type: COMPARATOR
Intervention: Non-active gel (control group)
Number of subjects: 22
Study 22914905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine (10 mg/day, increased to 20 mg/day)
Number of subjects: 70
Study 22914905 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg/day, increased to 5 mg/day)
Number of subjects: 70
Study 22914905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 70
Study 22914905 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 70
Study 21781356 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard PN solutions
Number of subjects: 0
Study 21781356 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomised analyses of neonatal aluminium intake above the median
Number of subjects: 0
Study 18414860 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency (RF)
Number of subjects: 40
Study 18414860 — intervention group
Group type: COMPARATOR
Intervention: Monopolar radiofrequency (RF)
Number of subjects: 40
Study 16454838 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg b.i.d.
Number of subjects: 124
Study 16454838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 14726063 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified parasternal wire closure (subgroup II B, n = 386)
Number of subjects: 1336
Study 14726063 — intervention group
Group type: COMPARATOR
Intervention: Conventional sternal closure (subgroup II A, n = 390)
Number of subjects: 1336
Study 14726063 — intervention group
Group type: COMPARATOR
Intervention: Standard six wire closure (Group I, n = 560)
Number of subjects: 1336